Key Takeaways
- • Epicutis secured a $25 million minority investment from private equity firm GroundForce Capital, positioning the round as a Series C funding event for the science-backed dermocosmetics brand.
- • GroundForce Capital will secure board representation as part of the deal, signaling active involvement in strategic oversight and governance alongside the company's founder-led leadership structure.
- • The company has demonstrated exceptional revenue growth, scaling at nearly 100% compound annual growth rate over the past two years, with reported progression from $350,000 in year one to $13 million in annual revenue.
- • Capital deployment will target expansion across the professional channel (medispas, clinics, spas), brand awareness initiatives, and advancement of the company's proprietary, patent-protected active ingredients including TSC, DSD, and HYVIA.
- • Epicutis differentiates through minimalist formulations backed by published scientific literature and clinical practitioner validation before consumer commercialization, a positioning that resonated with GroundForce's investment thesis.
Summary
Epicutis, a biotechnology-derived skincare brand positioned in the professional dermocosmetics channel, has completed a $25 million minority growth investment from GroundForce Capital. The funding represents a Series C capital raise and reflects continued institutional interest in science-backed cosmetics platforms with proprietary intellectual property.
The investment will support Epicutis' expansion strategy across multiple vectors: scaling presence within the professional channel (medispas, clinics, and spas), building brand awareness within institutional practitioner networks, and accelerating the discovery and development pipeline for new skincare innovations. GroundForce Capital will assume a board seat as part of the investment agreement, indicating hands-on involvement in strategic execution and governance.
Epicutis has built its commercial foundation on a disciplined scientific approach centered on patent-protected, biotechnology-derived active ingredients—specifically TSC, DSD, and HYVIA—formulated into minimalist products designed around skin health optimization. According to co-founder and CEO Maxwell Stock, the company's differentiation rests on validating active ingredients through published scientific literature and practitioner validation before market introduction. Stock characterized GroundForce's investment thesis as aligned with this rigor: "GroundForce [Capital] understood that discipline from our very first conversation."
The company's revenue trajectory demonstrates market traction in the professional channel. Epicutis has achieved near-100% compound annual growth rate over the prior two years, with reported revenue progression from $350,000 in year one to $13 million in current-year run rate. This growth within a niche professional distribution model suggests strong unit economics and repeat purchase behavior from institutional customers.
GroundForce Capital's investment underscores broader institutional appetite for differentiated platforms within the professional skincare market, particularly those combining proprietary biotech-derived formulations with defensible intellectual property and disciplined go-to-market execution concentrated on practitioner channels rather than direct-to-consumer retail.
The investment will support Epicutis' expansion strategy across multiple vectors: scaling presence within the professional channel (medispas, clinics, and spas), building brand awareness within institutional practitioner networks, and accelerating the discovery and development pipeline for new skincare innovations. GroundForce Capital will assume a board seat as part of the investment agreement, indicating hands-on involvement in strategic execution and governance.
Epicutis has built its commercial foundation on a disciplined scientific approach centered on patent-protected, biotechnology-derived active ingredients—specifically TSC, DSD, and HYVIA—formulated into minimalist products designed around skin health optimization. According to co-founder and CEO Maxwell Stock, the company's differentiation rests on validating active ingredients through published scientific literature and practitioner validation before market introduction. Stock characterized GroundForce's investment thesis as aligned with this rigor: "GroundForce [Capital] understood that discipline from our very first conversation."
The company's revenue trajectory demonstrates market traction in the professional channel. Epicutis has achieved near-100% compound annual growth rate over the prior two years, with reported revenue progression from $350,000 in year one to $13 million in current-year run rate. This growth within a niche professional distribution model suggests strong unit economics and repeat purchase behavior from institutional customers.
GroundForce Capital's investment underscores broader institutional appetite for differentiated platforms within the professional skincare market, particularly those combining proprietary biotech-derived formulations with defensible intellectual property and disciplined go-to-market execution concentrated on practitioner channels rather than direct-to-consumer retail.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.